Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MOBI
MOBI logo

MOBI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Mobia Medical Inc (MOBI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
13.500
1 Day change
3.05%
52 Week Range
--
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

MOBI is not a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. There is no usable trend, financial, or valuation data to support a confident entry, and the stock has no strong proprietary buy signal today. With no recent news, no options signal, neutral insider and hedge fund activity, and no evidence of a bullish catalyst, the setup is too weak for an immediate long-term purchase.

Technical Analysis

No stock trend data is available, so a true technical trend assessment cannot be confirmed. The only usable price reference is the pre-market price of 13.22, but without historical trend, support/resistance, volume, or momentum data, there is no technical evidence of a strong uptrend or breakout. Based on the missing trend data, the current chart setup is neutral to unconfirmed rather than bullish.

Positive Catalysts

  • ["No recent news was reported, so there are no fresh negative developments.", "Hedge funds are neutral, which at least suggests no strong institutional selling pressure.", "Insiders are neutral, so there is no obvious insider selloff."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no event-driven catalyst supporting the stock.", "No valuation data is available, making it difficult to justify the current price.", "Financial snapshot data is unavailable due to an error, so recent operating momentum cannot be assessed.", "No recent congress trading data is available.", "AI Stock Pick shows no signal today.", "SwingMax shows no recent signal.", "Stock trend data is unavailable, so there is no confirmation of a favorable price trend."]

Financial Performance

Financial performance cannot be meaningfully assessed because the latest quarter data is unavailable due to an error. The latest quarter season is not provided, so growth trends in revenue, earnings, or margins cannot be confirmed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided. Therefore, there is no evidence of improving Wall Street sentiment, and the current pros-versus-cons view is neutral to weak due to the lack of supporting analyst coverage changes.

Wall Street analysts forecast MOBI stock price to rise
0 Analyst Rating
0
Wall Street analysts forecast MOBI stock price to rise
0 Buy
0 Hold
0 Sell
0
Current: 13.100
sliders
Low
0
Averages
0
High
0
0
Current: 13.100
sliders
Low
0
Averages
0
High
0
BofA
NULL
to
Buy
initiated
$16
AI Analysis
2026-06-02
New
Reason
BofA
Price Target
$16
AI Analysis
2026-06-02
New
initiated
NULL
to
Buy
Reason
As previously reported, BofA initiated coverage of Mobia Medical with a Buy rating and $16 price target. Mobia has a first mover advantage with its vagus nerve stimulator Vivistim system for chronic stroke survivors and no competition on the horizon, says the analyst, who sees \"a long growth runway ahead.\"
BTIG
Buy
initiated
$19
2026-06-02
New
Reason
BTIG
Price Target
$19
2026-06-02
New
initiated
Buy
Reason
BTIG initiated coverage of Mobia Medical with a Buy rating and $19 price target. The company develops and commercializes Vivistim, the first and only FDA-approved vagus nerve stimulator platform for chronic ischemic stroke survivors living with moderate-to-severe upper extremity impairment, the analyst tells investors in a research note. BTIG says Mobia \"is not competing in an established market, it is the market.\" The firm views Mobia as a \"high-conviction, longhorizon market development story.\"
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MOBI
Unlock Now

People Also Watch